Joined the stock exchange: Almeda Ventures raised about NIS 69 million


New entrant to the stock exchange: The R&D partnership in the field of life sciences, Alameda Ventures, has completed an immediate fundraising of approximately NIS 69 million.

Alameda is led by Tzachi Sultan, chairman of Discount Capital Underwriting, and who led the issuance of many biomed companies on the Tel Aviv Stock Exchange at the end of the previous decade, along with Dr. Irit Yaniv and Amir Blatt, who are retiring from the fund management group. Axelmed risk managed by Uri Geiger.

Among the investors who participated in the fundraising are the founders of the partnership (about 10%), the Phoenix Insurance Company, the investment company of Vincent Changwiz, investors in the field of life sciences, other institutional investors and the public.

Recently, the stock exchange allowed the issuance of partnerships in R&D companies after until then it was allowed to raise capital in this way for oil and gas exploration partnerships (and also for the film industry – which was unsuccessful). , And investors need to take into account binary opportunities – huge success or a complete crash.

The companies in Almeda’s portfolio at present are Bioprotect and TaylorMurmed, both companies in which Yaniv and Blatt have also invested in an Axelmed hat. Bioprotect, founded in 2004, has developed a silicone implant designed to protect vital organs during radiation to the prostate. Alameda is expected to complete a $ 3 million investment in the company after the IPO. Tailormed, which has developed financial management software for healthcare, medical clinics and the patient itself, has raised about $ 9 million to date (of which Almeda’s share is $ 1 million after the IPO).

The partnership plans to invest in companies in Israel and abroad with research and development projects in the field of digital health and medical devices, with the aim of building a diverse portfolio with exits expected of 1-5 years. The capital invested will be directed to the clinical trial required to obtain FDA approval, and start sales.

Source link by

*The article has been translated based on the content of Source link by
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!


Please enter your comment!
Please enter your name here